Transcept shares soar on revived NDA hopes for Intermezzo

Shares of Transcept Pharmaceuticals ($TSPT) shot up more than 70% after the biotech laid out plans to resubmit its sleep drug Intermezzo to the FDA--after the agency green-lighted its plan to adjust dosing based on gender and fine-tune the timing instructions on the label. Transcept was handed a rejection on Intermezzo a few months ago after regulators raised a red flag that the drug--a...